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Aims Risk stratiﬁcation in individuals with type 1 Brugada electrocardiogram (ECG) pattern (type 1 ECG) for primary pre-
vention of sudden death (SD).
Methods
and results
Three hundred and twenty patients (258 males, median age 43 years) with type 1 ECG were enrolled. No patient had
previous cardiac arrest. Fifty-four per cent of patients had a spontaneous and 46% a drug-induced type 1 ECG. One-
third had syncope, two-thirds were asymptomatic. Two hundred and forty-ﬁve patients underwent electrophysiolo-
gic study (EPS) and 110 patients received an implantable cardiac deﬁbrillator (ICD). During follow-up [median length
40 months (IQ20-67)], 17 patients had major arrhythmic events (MAE) (14 resuscitated ventricular ﬁbrillation (VF)
and three SD). Both a spontaneous type 1 ECG and syncope signiﬁcantly increased the risk (2.6 and 3.0% event rate
per year vs. 0.4 and 0.8%). Major arrhythmic events occurred in 14% of subjects with positive EPS, in no subjects with
negative EPS and in 5.3% of subjects without EPS. All MAE occurred in subjects who had at least two potential risk
factors (syncope, family history of SD, and positive EPS). Among these patients, those with spontaneous type 1 ECG
had a 30% event rate.
Conclusion (1) In subjects with the Brugada type 1 ECG, no single clinical risk factor, nor EPS alone, is able to identify subjects at
highest risk; (2) a multiparametric approach (including syncope, family history of SD, and positive EPS) helps to ident-
ify populations at highest risk; (3) subjects at highest risk are those with a spontaneous type 1 ECG and at least two
risk factors; (4) the remainder are at low risk.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Brugada type 1 electrocardiogram (ECG) pattern is characterized
by coved-type ST segment elevation (.2 mm) in the right precor-
dial leads.
1–5 This pattern may be present in the basal ECG or be
unmasked by the infusion of Na channel-blocking drugs in subjects
with type II or III ECG patterns.
6–8
Individuals with type 1 Brugada ECG pattern may suffer from
malignant ventricular arrhythmias (Brugada syndrome).
9–11 It is
generally agreed that patients with Brugada syndrome and
*Corresponding author: Tel: +39 043 866 3613, Fax: +39 043 866 3759, Email: alloccag75@libero.it
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2010. For permissions please email: journals.permissions@oup.com.
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article
for non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the
original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this
must be clearly indicated. For commercial re-use, please contact journals.permissions@oup.com.
European Heart Journal (2011) 32, 169–176
doi:10.1093/eurheartj/ehq381documented cardiac arrest should receive an implantable cardiac
deﬁbrillator (ICD). In the remaining subjects, the best policy is
controversial.
12
Many data
13–22 suggest that patients with syncope, particularly if
they have a spontaneous type 1 ECG pattern, have a signiﬁcant
risk; some authors
13–17 therefore suggest ICD implantation in
these cases, too. In the remaining population of asymptomatic sub-
jects, the risk is lower but not negligible.
13,17 How to manage these
latter cases, and in particular how to recognize those at highest risk
who would beneﬁt from ICD implantation,
23,24 is an unsolved
issue.
The usefulness of electrophysiologic study (EPS) in risk strati-
ﬁcation, i.e. the inducibility of sustained ventricular tachycardia/
ventricular ﬁbrillation (VT/VF) is controversial.
17,25–27 Indeed,
some authors, particularly the Brugada brothers,
10,13,14 strongly
support the prognostic value of EPS, while others
15,16,19 comple-
tely deny its usefulness.
To address the problem of risk stratiﬁcation in subjects with
type 1 Brugada pattern, we analysed the prospective experiences
of ﬁve Italian centres. The aim was to evaluate the usefulness of
a combined approach that considered both clinical data and the
results of EPS.
Methods
Study population
This prospective study involved 320 patients (258 males, mean age
43+ years) with type 1 Brugada pattern enrolled in ﬁve Italian
centres since 1998: Conegliano, Asti, Rome, Udine, and Portogruaro.
No patient had previous cardiac arrest or documented VT/VF.
In accordance with current guidelines, the type 1 Brugada ECG
pattern was deﬁned in the presence of coved ST elevation (.2 mm)
in one or more leads from V1 to V3, either spontaneous or induced
by class I anti-arrhythmic drug administration (I-type 1). Spontaneous
type 1 pattern was deﬁned when at least one ECG documented a
type 1 pattern in the absence of anti-arrhythmic drugs. A type 1
ECG pattern recorded in II–III intercostals spaces was considered diag-
nostic. Type II ECG pattern was deﬁned in the presence of a .2m mJ
point elevation and .1 mm saddleback-type ST elevation with positive
T wave. Type III pattern was deﬁned as a ,1 mm saddleback- or
coved-type ST elevation. Sodium channel blockers used were ﬂecai-
nide (2 mg/kg i.v. in 10 min) or ajmaline (1 mg/kg i.v. in 5 min).
Testing was performed in subjects with type II or III patterns. The
test was considered positive only if a coved-type 1 ECG pattern was
documented. Individuals with type II or III patterns in whom anti-
arrhythmic drugs did not reproduce a type 1 pattern were excluded
from the study.
All ECG of patients participating in the study were analysed by a
central board.
In all patients with spontaneous or drug-induced type 1 pattern, a
thorough family history was collected in order to search for subjects
who had died suddenly with a type 1 Brugada ECG pattern or
before the age of 40 years in the absence of known heart disease.
Patients without syncope were regarded as asymptomatic. Syncope
was deﬁned as loss of consciousness in accordance with the current
literature. For the purpose of this paper, no attempt was made to
differentiate vaso-vagal from possible arrhythmic forms. All syncopes
were therefore included. Patients with resuscitated cardiac arrest
were excluded from this study.
All patients underwent echocardiography, laboratory tests, and
other examinations, if appropriate, in order to exclude the presence
of an underlying structural heart disease. In all cases, EPS was
proposed.
Electrophysiologic study
After informed written consent had been obtained, EPS including ven-
tricular premature stimulation (VPS) was carried out. Ventricular pre-
mature stimulation was performed at two right ventricular sites: ﬁrst at
the apex and then at the outﬂow tract. Ventricular premature stimu-
lation was carried out in the different centres by utilizing two proto-
cols with comparable aggressiveness. Protocol A included two
pacing cycle lengths (600 and 400 ms) with up to two extrastimuli.
The extrastimuli were anticipated in 10 ms decrements up to the
shortest coupling interval that resulted in ventricular capture. Protocol
B included two pacing cycle lengths (600 and 400 ms) with up to three
extrastimuli. The extrastimuli were anticipated in 10 ms decrements up
to a shortest coupling interval of 200 ms.
The endpoint of VPS was the induction of a sustained ventricular
arrhythmia (polymorphic or monomorphic ventricular tachycardia,
VF) leading to collapse and requiring shock or the completion of the
protocol. Positive EPS was deﬁned when a sustained ventricular
arrhythmia (.30′) requiring shock was induced. Negative EPS was
deﬁned when no ventricular arrhythmia or a self-terminating ventricu-
lar arrhythmia was induced but did not require shock.
Protocol A was employed in 91 cases, protocol B in 154. In 75 cases,
EPS was not performed.
Implantable cardiac deﬁbrillator
implantation
Patients were informed of their potential risk, which was based mainly
on the presence of a spontaneous type 1 pattern and a history of
syncope. The prognostic value of a family history of sudden death
(SD) and of inducibility of VT/VF by EPS was explained as questionable
risk factors. The decision to implant an ICD was taken after written
informed consent had been provided.
All ICD implanted were capable of recording and storing ECG data
at the time of episodes of shock. Detailed ICD programming was left
to investigator preference, also on the basis of the different devices
employed. However, in all cases, a single VF zone was programmed
with a lower detection rate of 180 b.p.m. Ventricular back-up pacing
was programmed at a rate of 35–50 b.p.m.
Follow-up
Follow-up examinations were performed every 6 months or in the
event of symptoms. All patients were called for the last follow-up
examination between January and June 2009. All patients were fol-
lowed up for at least 1 year. Ten patients were lost to the last
follow-up examination. In patients with ICD, analysis of arrhythmias
and of appropriate and inappropriate shocks was also performed.
Patients were considered to have major arrhythmic events (MAE) if
they suddenly died or if VT/VF was recorded by the implanted ICD
or by conventional ECG.
Statistical analysis
Statistical analysis was carried out with Systat 12 (2008, Chicago, IL,
USA) and JMP 4.0 for Windows (SAS Institute, 2000, Cary, NC,
USA) packages. For continuous variables (after checking they had
normal distribution), comparisons among groups were made by
means of Student’s t-test or ANOVA. Pearson’s x
2-test was used for
categorical variables. Event analysis over time was made by using the
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hazard ratio with 95% conﬁdence interval (CI). Survival curves were
constructed by means of the Kaplan–Meier method and compared
by the log-rank test. For event prediction, C-statistic analysis was
used. Like the area under the ROC curve, the C-statistic ranges
from 0.5 (i.e. no discrimination) to 1.0 (maximum discrimination
ability).
Data are presented as medians and interquartiles for continuous
measures and as proportions for categorical variables. All P values
are two-tailed, and statistical signiﬁcance was established as P , 0.05.
Results
Clinical characteristics
Table 1 shows the clinical and ECG characteristics of patients. In
brief, 54% of patients had a spontaneous type 1 pattern, while in
the remainder, a type 1 ECG pattern was induced by anti-arrhythmic
drugs. Ninety-four patients (29%) had a family history of SD.
About one-third of patients had syncopal episodes, while
two-thirds were asymptomatic. Among the latter, 46 had a
family history of SD and 40 had a history of Brugada syndrome
(without familial SD), while 129 had neither a family history of
SD nor a family history of Brugada syndrome.
Electrophysiologic study
Electrophysiologic study was performed in 245 patients; 75
patients refused EPS. Table 2 summarizes the clinical characteristics
of subjects who underwent EPS and of those who did not. In
general, the two groups were similar, with the exception of a
higher prevalence of syncope in patients who underwent EPS.
Positive EPS included the induction of polymorphic VT/VF in
all but three cases. In these three cases, a fast monomorphic sus-
tained VT was induced. In all cases, induced arrhythmias required
shock.
As shown in Table 3, EPS was positive in 50% of symptomatic vs.
32% of asymptomatic subjects (P ¼ 0.07). Furthermore, EPS was
positive in 49% of subjects with spontaneous type 1 ECG
pattern vs. 26% of those with drug-induced type 1 ECG pattern
(P ¼ 0.43). Electrophysiologic study was positive in 35/91 (38%)
patients who underwent protocol A and in 61/154 (39%) patients
who underwent protocol B (P ¼ 0.84). VT/VF was induced by a
single extrastimulus in 2%, by double extrastimuli in 74%, and by
triple extrastimuli in 24% (2/96, 71/96, and 23/96, respectively).
Implantable cardiac deﬁbrillator
implantation
Implantable cardiac deﬁbrillators were implanted in 110 patients.
The clinical and EPS characteristics of these patients are summar-
ized in Table 4. In brief, 84% were males, 38% had a family history
of SD, 74% had a spontaneous type 1 ECG pattern, 58% had
syncope, and 81% had a positive EPS.
Follow-up
During follow-up [median length 40 months (IQ20-67)], 17
patients suffered MAE (14 VF recorded by ICD and three SDs).
Among the 14 VF, which were interrupted by the ICD, the
shock was delivered 10–22′ after the onset of the arrhythmia.
Major arrhythmic events occurred in 10.4% of symptomatic and
2.8% of asymptomatic subjects.
................................................................................
................................................................................
Table 1 Baseline characteristics of the entire
population of 320 patients
Median (IQ) age 43 (33–54)
Male sex 258 (81%)
Resting ECG
Type 1 174 (54%)
Type 2 90 (28%)
Type 3 56 (17%)
Positive family history of sudden death 94 (29%)
Syncope 105 (34%)
EPS performed 245 (77%)
ICD implanted 110 (34%)
................................................................................
Table 2 Clinical differences between patients who
underwent electrophysiologic study(EPS) (n 5 245) and
those who did not (n 5 75)
EPS NP
(n 5 75)
EPS
(n 5 245)
P-value
Age (years) 41 (IQ 32–53) 44 (IQ 34–53) 0.31
Sex (male) 81% 80% 0.85
Family history of
SCD
23% 31% 0.14
History of syncope 18% 37% 0.003
Basal type 1 ECG
pattern
45% 57% 0.072
EPS NP, EPS not performed.
................................................................................
Table 3 Percentages of positive electrophysiologic
study (EPS) (EPS1) in the entire population of 245
patients who underwent EPS, and in different subsets of
patients: symptomatic, asymptomatic, basal type 1
ECG, type 1 ECG induced by drugs
n EPS1 (n) % EPS1
All patients 245 96 39
Symptomatic
a 91 46 50
Asymptomatic 154 50 32
Basal type 1 ECG 140 69 49
Drug-induced type 1 ECG 105 27 26
aSymptomatic for syncope.
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The following variables were analysed as potential predictors of
MAE: age, gender, syncope, basal type 1 ECG, and family history
of SD.
Table 5 shows outcome rate per year by risk factor, a signiﬁ-
cantly increased risk was associated with basal type 1 ECG and
syncope, which displayed 2.6 and 3.0% event rates, respectively.
Male gender (1.7% event rate per year) and family history of SD
(2.2% event rate per year) showed only a trend towards increased
risk. On univariate and multivariate analysis, a signiﬁcant increase in
risk was found for basal type 1 ECG and syncope (Table 6).
Role of electrophysiologic study as a
single predictor of outcome
Major arrhythmic events occurred in 14% of patients with positive
EPS, in 0% of those with negative EPS, and in 5.3% of those who did
not undergo EPS (P , 0.001). The positive predictive value of EPS
was therefore 14% and the negative predictive value was 100%.
In subjects with positive EPS, MAE occurred in 17% of those
who underwent protocol A and in 11.4% of those who underwent
protocol B (6/35 and 7/61, respectively, P ¼ 0.40).
Major arrhythmic events occurred in 0, 15.5, and 8.6% of
patients in whom VT/VF was induced by single, double, and
triple extrastimuli, respectively (0/2, 11/71, 2/23, P ¼ 0.23).
Multiparametric (clinical and
instrumental) risk stratiﬁcation
As shown in Table 7, the presence of one clinical risk factor dis-
played only a low ability to predict MAE (C-statistics 0.58–0.71).
By contrast, an increased risk was observed on combining two
or more clinical risk factors (C-statistics 0.66–0.77). The combi-
nation best able to predict MAE was spontaneous type 1
pattern, family history of SD, and syncope (C-statistics 0.77; 95%
CI: 0.71–0.82). A positive EPS increased the ability of clinical
factors to predict the risk (D C-statistic 0.11–0.21).
In the group of 245 patients who underwent EPS, the combi-
nation best able to predict major events was that of syncope,
basal type 1 ECG, family history of SD, and positive EPS (C-statistic
0.87; 95% CI: 0.82–0.90).
In those patients who underwent EPS, Kaplan–Meier curves
were plotted on considering three risk factors: syncope, family
history of SD, and positive EPS. No events occurred in subjects
without any of these risk factors or with only one. Indeed, MAE
occurred only in subjects with two or three risk factors (P ,
0.001) (Figure 1).
In the subgroup of 140 patients with a spontaneous type 1
pattern (Figure 2), MAE occurred in about 30% of subjects with
................................................................................
................................................................................
Table 5 Outcome rate per year by risk factor in the
entire population of 320 patients
Events rate per year (%) P-value
Age
.43 years 1.9 0.47
,43 years 1.3
Male 1.7 0.41
Female 0.9
Syncope 3.0 0.004
No syncope 0.8
Basal type 1 ECG 2.6 0.004
1C ECG 0.4
Family history 2.2 0.27
No family history 1.3
............................................................ ................................................................
...............................................................................................................................................................................
Table 6 Univariate and multivariate analysis in the entire population of 320 cases
Univariate analysis Multivariate analysis
Hazard ratio 95% CI P Hazard ratio 95% CI P-value
Age (per year) 0.9 0.8–1.0 0.19 – – –
Male 2.1 0.6–13.3 0.28 – – –
Syncope 3.1 1.2–9.2 0.01 2.8 1.1–8.1 0.03
Basal type 1 ECG 6.6 1.8–41.8 0.001 6.2 1.8–39.9 0.002
Family history of SD 1.9 0.7–4.8 0.22 – – –
................................................................................
Table 4 Clinical and electrophysiologic
characteristics of patients who received [implantable
cardiac deﬁbrillator (ICD)] or did not receive (no ICD)
an ICD
No ICD
(n 5 210)
ICD (n 5 110) P-value
Male 165 (78%) 93 (84%) 0.25
Syncope 41 (19%) 64 (58%) ,0.001
Basal type 1 ECG 92 (44%) 82 (74%) ,0.001
EPS+ 6/139 (4%) 90/106 (85%) ,0.001
Family history of SD 52 (25%) 42 (38%) 0.02
Median (IQ) 41 (21–67) 40 (23–67) 0.73
follow-up (months)
The entire population comprised 320 patients. The results of EPS refer to a subset
of 245 patients who underwent EPS. EPS+ ¼ positive EPS.
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(Figure 3), i.e. those with a type 1 ECG pattern induced by anti-
arrhythmic drugs, only two MAE occurred in subjects with two
risk factors (P ¼ 0.12).
Discussion
Malignant arrhythmias and SD can occur in subjects with the
Brugada type 1 ECG pattern. In early reports,
13–17 malignant
arrhythmias and SD were reported to be frequent. More recent
papers, however, have shown that they are relatively rare.
10,11
Our study conﬁrms these latter data. In this prospective study,
which enrolled individuals with the type 1 ECG pattern without
previous cardiac arrest, malignant arrhythmias occurred in 5.3%
of cases. Speciﬁcally, they occurred in 10.4% of symptomatic and
2.8% of asymptomatic subjects (P ¼ 0.004) during a median
follow-up 3.3 years. It follows that malignant arrhythmias occurred
in 3.0 and 0.8%/patient/year in symptomatic and asymptomatic sub-
jects (P ¼ 0.004), respectively (Table 5).
In patients with Brugada syndrome and documented cardiac
arrest, ICD implantation is mandatory. In the remaining patients,
who constitute the vast majority of subjects encountered in the
clinical setting, the best policy is unclear.
12 The relative rarity of
fatal events, however, suggests that it is not reasonable to
implant an ICD in all subjects with a type 1 ECG pattern, particu-
larly if they have no symptoms. Therefore, the main problem is to
predict, in the setting of the entire population with the type 1 ECG
pattern, which subjects have the highest risk of suffering a poten-
tially fatal event.
...............................................................................................................................................................................
Table 7 Discriminate analysis by C-statistic in 245 patients who underwent electrophysiologic study (EPS) in whom all
risk factors were able to be evaluated
Clinical variables C-statistics (95% CI) EPS1 added (95% CI) D C-statistics P-value
Family history of SD (FAM) 0.58 (0.51–0.64) 0.79 (0.74–0.84) 0.21 ,0.001
Basal type 1 ECG (ECG) 0.64 (0.58–0.70) 0.82 (0.77–0.87) 0.18 ,0.001
Syncope (SYN) 0.71 (0.65–0.77) 0.86 (0.81–0.90) 0.15 ,0.001
FAM + ECG 0.66 (0.60–0.72) 0.81 (0.75–0.85) 0.15 ,0.001
FAM + SYN 0.73 (0.68–0.80) 0.87 (0.82–0.91) 0.14 ,0.001
ECG + SYN 0.76 (0.70–0.81) 0.87 (0.82–0.91) 0.11 ,0.001
FAM + ECG + SYN 0.77 (0.71–0.82) 0.87 (0.82–0.90) 0.10 0.001
In the ﬁrst column, clinical variables are analysed singly and in different combinations. In the fourth column, the added value of EPS is shown and expressed as delta
C-statistics.
Figure 1 Kaplan–Meier survival curves in the entire population
of 245 patients who underwent electrophysiologic study (EPS).
Risk factors considered were: family history of sudden death,
syncope, and positive EPS. Curves are plotted according to the
presence of 0, 1, 2, or 3 risk factors.
Figure 2 Kaplan–Meier survival curves in the population of
140 patients with basal type 1 ECG who underwent electrophy-
siologic study (EPS). Risk factors considered were: familial history
of sudden death, syncope, and positive EPS. Curves are plotted
according to the presence of 0, 1, 2, or 3 risk factors.
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type 1 ECG pattern proved to be a clinical risk factor, both on uni-
variate and multivariate analysis (Table 6). On the other hand, a
type 1 ECG pattern induced only by drugs identiﬁed subjects at
low risk. Speciﬁcally, major events occurred in 8.6% of patients
with a spontaneous type 1 ECG pattern vs. 1.3% of those with a
drug-induced type 1 ECG pattern (P ¼ 0.004). A history of
syncope was conﬁrmed to be a risk factor (10.4% event rate vs.
2.8% in asymptomatic patients, P ¼ 0.004). Finally, a family
history of SD was conﬁrmed to be a weak risk factor (7.4 vs.
4.4%, P ¼ 0.27). In general, however, all three clinical risk factors
showed a low positive predictive value (8.6, 10.4, and 7.4%,
respectively).
In the current literature, the predictive value of EPS is contro-
versial.
23,24 Indeed, while some authors
13,14 report a high prognos-
tic signiﬁcance of EPS, others deny its usefulness. However, many
of the multicentre studies that have indicated the scant usefulness
of EPS display major methodological problems. In particular, these
studies used heterogeneous stimulation protocols.
15,16,19,25–27
Furthermore, the precise protocols are often not clearly speciﬁed.
For example, some authors simply state that ‘heterogeneous pro-
tocols were used’,
15 while others use ambiguous deﬁnitions, such
as ‘up to three extrastilmuli were employed’,
19 which does not
indicate whether all patients had triple extrastimuli or whether
some underwent a less aggressive protocol. The latter hypothesis
seems more probable in a recent large multicentre study by Probst
et al.,
19 on the basis of the previously published experiences of the
participating centres.
It follows that the category of patients with negative EPS may
include those in whom the non-inducibility of VT/VF is due to
the low intensity of stimulation. In other words, it is possible
that some of them would have a positive EPS if more aggressive
stimulation were used.
In our multicentre study, two comparably aggressive protocols
were employed, and were completed in all cases. As a result, in
agreement with many authors, our EPS was frequently positive in
both symptomatic and asymptomatic subjects. Indeed, in our
study, EPS was positive in 50% of symptomatic and 32% of asymp-
tomatic subjects. Consequently, when considered alone, EPS dis-
played a low positive predictive value (14%). Thus, a positive EPS
cannot be considered a gold standard with regard to the decision
to implant an ICD.
By contrast, EPS showed a 100% negative predictive value.
Indeed, major events occurred only in subjects with positive EPS
(14%), while no MAE occurred in patients with negative EPS.
The latter data, which conﬂict with the results of other authors,
may be simply explained by the fact that all our patients underwent
an aggressive protocol.
In any case, despite the limit of low positive predictive values,
our data support the usefulness of EPS in evaluating risk in subjects
with the type 1 Brugada pattern, as proposed by the Brugada
brothers
13,14 and others.
18 In particular, it can help to identify sub-
jects at low risk, i.e. those who really do have a negative EPS. This
information is lacking in patients who do not undergo EPS; in our
study, 5.3% of these patients suffered MAE.
Considering that subjects with the Brugada type 1 ECG pattern
may have different risk factors, each of which, however, when con-
sidered singly, has a low predictive value, we decided to evaluate
the usefulness of a multiparametric, clinical, and electrophysiologic
approach. In this way, we identiﬁed different populations of
patients at increasing risk, in whom multiple clinical risk factors
were present: basal type 1 ECG, family history of SD, and syncope.
On combining two or more clinical risk factors, an increasing
risk was observed (C-statistic 0.66–0.77), the combination best
able to predict MAE being a spontaneous type 1 ECG pattern,
family history of SD, and syncope (C-statistics 0.77; 95% CI:
0.71–0.82). A positive EPS increased the ability of clinical risk
factors to predict outcome (D C-statistic 0.11–0.21).
In the group of 245 patients who underwent EPS, the combi-
nation best able to predict major events was that of syncope,
basal type 1 ECG, family history of SD, and positive EPS (C-statistic
0.87; 95% CI: 0.82–0.90).
On analysing Kaplan–Meier curves plotted on the entire popu-
lation, with spontaneous or drug-induced type 1 pattern, all events
were seen to have occurred in subjects who had at least two of the
main risk factors (family history of SD, syncope or EPS+), while no
events occurred in those without or with only one risk factor.
In other words, in this study, no subject without a family history
of SD, without syncope, and with negative EPS suffered events.
Furthermore, no patient with only one risk factor had events.
This means that, when considered individually, familial SD,
syncope, and positive EPS did not predict the occurrence of
events.
Events occurred only in patients with spontaneous or
drug-induced type 1 pattern in whom two or three of the
factors were present (i.e. syncope + positive EPS, familial SD +
syncope, familial SD + positive EPS, or all three together). In sub-
jects with spontaneous type 1 ECG pattern and two or more risk
Figure 3 Survival Kaplan–Meier curves in the population of
105 patients with drug-induced type 1 ECG who underwent elec-
trophysiologic study (EPS). Risk factors considered were: family
history of sudden death, syncope, and positive EPS. Curves are
plotted according to the presence of 0, 1, 2, or 3 risk factors.
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ECG, the risk was very low (,2%) and was conﬁned to subjects
with two risk factors. This latter ﬁnding suggests a limited clinical
value of the drug test when Brugada syndrome is only suspected
(type II or III ECG) in the absence of symptoms and of a family
history of SD.
Study limitations
This prospective study assembled two similar prospective studies
performed by two groups of centres. One group employed proto-
col A; the other employed protocol B. The two protocols were
not identical, but both were aggressive. Therefore, they were
judged comparable. The results, which showed 38 and 39% of posi-
tive EPS with the two protocols, respectively, conﬁrm that this was
indeed the case.
The choice of performing or not performing EPS, after informed
consent had been given, depended on the decision of each single
patient. A higher proportion of patients who underwent EPS had
syncope and a family history of SD. These characteristics probably
inﬂuenced the individual decision to undergo EPS. During
follow-up, major events occurred in 4/75 (5.3%) patients who
did not undergo EPS and in 13/245 (5.3%) who did. As there is
no difference between these percentages, it seems that the differ-
ences between these two populations did not inﬂuence the
outcome.
The events evaluated during follow-up (MAE) included SD
and ICD-recorded fast VT/VF which were converted by
means of shock. Sustained VT/VF interrupted by shock is only a
surrogate of SD. Indeed, we cannot claim that patients in
whom sustained VT/VF was interrupted by ICD would have died
suddenly in the absence of the device. On the other hand, as an
ICD was implanted in about one-third of cases, we cannot
exclude the possibility that the remaining two-thirds of patients
had asymptomatic, self-terminating VT/VF. Notably, patients
with ICD more frequently had clinical risk factors, particularly
positive EPS.
Conclusions
Risk stratiﬁcation in subjects with type 1 Brugada ECG pattern is a
complex problem. In our study, we analysed several risk factors,
which, however, when considered singly, displayed a low positive
predictive value: basal type 1 pattern, syncope, familial SD, and
positive EPS. We therefore propose a multiparametric (clinical
and electrophysiologic) approach which helps to identify popu-
lations at higher risk.
On the basis of our data, subjects at higher risk are those with
a basal type 1 ECG pattern who have at least two of the follow-
ing risk factors: syncope, family history of SD, and positive EPS.
Even in the presence of a basal type 1 ECG, no single risk
factor, including EPS, is able to identify subjects at the highest
risk. Electrophysiologic study may be useful when evaluated
together with other clinical risk factors. A positive EPS together
with other risk factors helps in deciding on ICD implantation. A
negative EPS (using an aggressive protocol) can help to avoid ICD
implantation. Patients with a drug-induced type 1 ECG have a
very low risk; in the absence of other risk factors, EPS is of
scant usefulness.
Our conclusions support the suggestions of the second consen-
sus conference by Antzelevitch et al. published in 2005.
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